ABBV
HEALTHCAREAbbvie Inc
$205.03-1.08 (-0.52%)PRE
Live · NYSE · May 8, Close
AI Insight
What's Moving ABBV Today?
No stock-specific AI insight has been generated for ABBV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$171.00$239.13
$205.03
Fundamentals
Market Cap$362.6B
P/E Ratio100.5
EPS$2.04
Dividend Yield0.03%
Dividend / Share$6.74
ROE0.6%
Profit Margin0.1%
Debt / Equity—
Trading
Volume7.3M
Avg Volume (10D)—
Shares Outstanding1.77B
ABBV News
54 articles- AbbVie Inc. stock (US00287Y1091): Q1 2026 sales surge on immunology and aesthetics growthAD HOC NEWS·May 9, 2026
- Is It Time To Reassess Amgen (AMGN) After A Steady Share Price And Strong DCF CaseSimply Wall Street·May 9, 2026
- Assessing Regeneron (REGN) After Recent Share Price Weakness And Strong Valuation SignalsSimply Wall Street·May 8, 2026
- Ironwood Stock Down Despite Q1 Earnings and Revenue BeatYahoo Finance·May 8, 2026
- AbbVie’s Skyrizi beats out J&J’s Tremfya in in April drug ad spending leaderboardFierce Pharma·May 8, 2026
- AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award WinnerInsider Monkey·May 8, 2026
- Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain247 Wall St·May 7, 2026
- AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.Barchart·May 7, 2026
- Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?Yahoo Finance·May 7, 2026
- Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?Motley Fool·May 6, 2026
- This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A BreakoutYahoo Finance·May 6, 2026
- 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash247 Wall St·May 6, 2026
- DDW 2026: key readouts from the conferenceClinicaltrialsarena·May 6, 2026
- Timothy P. Walbert Joins Patient Square Capital as a Senior AdvisorYahoo Finance·May 6, 2026
- AbbVie to Present at the Bank of America Securities Healthcare ConferenceYahoo Finance·May 6, 2026
- Want Reliable Dividend Income in May? These 2 Stocks DeliverMotley Fool·May 6, 2026
- 3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic ValueYahoo Finance·May 5, 2026
- Want to Collect a High Dividend Every Month? Invest in These 3 StocksMotley Fool·May 5, 2026
- Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?Yahoo Finance·May 5, 2026
- Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab RealityYahoo Finance·May 5, 2026
- AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®Yahoo Finance·May 5, 2026
- 3 Stocks With Estimated Discounts Up To 44.8% Offering Value OpportunitiesYahoo Finance·May 5, 2026
- AbbVie's Latest Results Reveal a Trend Investors Shouldn't OverlookMotley Fool·May 4, 2026
- 3 of the Best Dividend Stocks to Buy in May 2026Motley Fool·May 4, 2026
- Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026GlobeNewswire Inc.·May 1, 2026
- AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in QuebecGlobeNewswire Inc.·Apr 30, 2026
- AbbVie et adMare BioInnovations nomment RIME Therapeutics lauréat du Prix AbbVie des innovateurs en biotechnologies au QuébecGlobeNewswire Inc.·Apr 30, 2026
- AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience StrengthBenzinga·Apr 29, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle DrugBenzinga·Apr 24, 2026
- Mental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FGlobeNewswire Inc.·Apr 24, 2026
- Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & OutlookGlobeNewswire Inc.·Apr 21, 2026
- Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological DiseasesGlobeNewswire Inc.·Apr 20, 2026
- The Psychedelic Revolution in Mental HealthcareThe Motley Fool·Apr 17, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- 3 Companies Aggressively Raising Dividends While Others Play DefenseInvesting.com·Apr 10, 2026
- 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing TreatmentsGlobeNewswire Inc.·Apr 10, 2026
- Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage PipelineGlobeNewswire Inc.·Apr 10, 2026
- Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033GlobeNewswire Inc.·Apr 10, 2026
Price Data
Open$206.11
Previous Close$206.11
Day High$207.01
Day Low$203.56
52 Week High$239.13
52 Week Low$171.00
52-Week Range
$171.00$239.13
$205.03
Fundamentals
Market Cap$362.6B
P/E Ratio100.5
EPS$2.04
Dividend Yield0.03%
Dividend / Share$6.74
ROE0.6%
Profit Margin0.1%
Debt / Equity—
Trading
Volume7.3M
Avg Volume (10D)—
Shares Outstanding1.77B
About Abbvie Inc
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—